The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How might emerging therapies and combination approaches reshape sequencing strategies in cGvHD?
During this interview, Zeiser discusses emerging treatment strategies under evaluation in cGvHD, including the latest clinical data for several combination approaches and novel agents. Whilst encouraging results have been observed to date, further research is needed to define their optimal placement within treatment sequencing pathways.
This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}